Nanobiotix S.A [NBTX] vs Vertex [VRTX] Detailed Stock Comparison

Nanobiotix S.A. - ADR

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Nanobiotix S.A. - ADR wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 14 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nanobiotix S.A. - ADR Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -67.61 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio N/A 5.92 N/A
Debt-to-Equity Ratio -1.33 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio 422.85 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -146.15 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -73.52% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -196.42% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity 28.36% 22.54% Nanobiotix S.A. - ADR
Return on Assets (TTM) -10.06% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-33.97M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 565.54% -2.31% Nanobiotix S.A. - ADR
Price-to-Sales Ratio (TTM) 45.83 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.81B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 47.03 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $1 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.59 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.55 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 0.07% 1.78% Nanobiotix S.A. - ADR

Nanobiotix S.A. - ADR vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

NBTX
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nanobiotix S.A. - ADR4.45%3.46%-27.92%9.18%66.16%67.74%
Vertex Pharmaceuticals Inc.1.24%1.69%3.09%-3.36%-1.15%-0.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nanobiotix S.A. - ADR565.54%580.84%144.77%109.31%109.31%109.31%
Vertex Pharmaceuticals Inc.-2.31%27.89%136.85%413.01%888.51%1,245.83%

Performance & Financial Health Analysis: Nanobiotix S.A. - ADR vs Vertex Pharmaceuticals Inc.

MetricNBTXVRTX
Market Information
Market Cap i$1.63B$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i71,2581,057,061
90 Day Avg. Volume i70,5261,272,097
Last Close$37.12$450.46
52 Week Range$4.18 - $57.14$362.50 - $507.92
% from 52W High-35.04%-11.31%
All-Time High$57.00 (May 14, 2026)$519.88 (Nov 04, 2024)
% from All-Time High-34.88%-13.35%
Growth Metrics
Quarterly Revenue GrowthN/A0.10%
Quarterly Earnings GrowthN/A0.31%
Financial Health
Profit Margin (TTM) i-0.74%0.33%
Operating Margin (TTM) i-1.96%0.40%
Return on Equity (TTM) i0.28%0.23%
Debt to Equity (MRQ) i-1.3310.91
Cash & Liquidity
Book Value per Share (MRQ)$-1.65$73.49
Cash per Share (MRQ)$1.09$26.01
Operating Cash Flow (TTM) i$-39,388,829$3.63B
Levered Free Cash Flow (TTM) i$-9,303,463$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nanobiotix S.A. - ADR vs Vertex Pharmaceuticals Inc.

MetricNBTX (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-67.6128.40
Forward P/E i422.8519.95
PEG Ratio i422.850.88
Price to Sales (TTM) i45.839.22
Price to Book (MRQ) iN/A5.92
Market Capitalization
Market Capitalization i$1.63B$109.45B
Enterprise Value i$1.81B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i47.038.83
Enterprise to EBITDA i-146.1521.78
Risk & Other Metrics
Beta i0.550.37
Book Value per Share (MRQ) i$-1.65$73.49

Financial Statements Comparison: Nanobiotix S.A. - ADR vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBTX (2025)VRTX (2025)
Revenue/Sales i29.64M12.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i23.12M4.04B
Operating Income (EBIT) i-10.82M4.55B
Operating Margin i-36.5%37.9%
EBITDA i-8.83M5.25B
EBITDA Margin i-29.8%43.7%
Pre-Tax Income i-23.96M4.64B
Pre-Tax Income % of Revenue i-80.8%38.7%
Income Tax i3,000690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-23.96M3.95B
Profit Margin i-80.8%32.9%

Balance Sheet & Liquidity Metrics

MetricNBTX (2025)VRTX (2025)
Cash & Equivalents i52.75M5.08B
Total Current Assets i62.75M11.20B
Total Current Assets % of Revenue i211.7%93.3%
Total Current Liabilities i57.51M3.86B
Total Current Liabilities % of Revenue i194.0%32.2%
Long-Term Debt i91.01M1.95B
Long-Term Debt % of Revenue i307.0%16.3%
Total Shareholders Equity i-84.48M18.67B
Retained Earnings i-23.96M13.56B
Retained Earnings % of Revenue i-80.8%113.0%
Property, Plant & Equipment i2.59M1.56B

Cash Flow Statement Comparison

MetricNBTX (2025)VRTX (2025)
Operating Cash Flow i-27.74M3.77B
Operating Cash Flow % of Revenue i-93.6%31.4%
Capital Expenditures i-538,000-437.60M
Free Cash Flow i-33.97M3.19B
FCF Margin i-114.6%26.6%
Debt Repayment i-4.74M-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricNBTXVRTX
Shares Short i25,4744.02M
Short Ratio i0.362.80
Short % of Float i0.07%1.78%
Shares Outstanding i48.39M253.99M
Float Shares i31.07M253.24M
% Held by Insiders i0.00%0.21%
% Held by Institutions i11.79%97.60%
% Held by Public i88.21%2.19%

Dividend Analysis & Yield Comparison: Nanobiotix S.A. - ADR vs Vertex Pharmaceuticals Inc.

MetricNBTXVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A